2024 Revenues ($USD) : $48.30B

Bristol Myers Squibb had solid growth in 2024 with total revenues of $45.5 billion, marking a 7% bump year-over-year. The company's fourth-quarter revenues reached $12.3 billion, up 8% (9% adjusted for foreign exchange).

Recent developments highlighted by the company include positive CHMP opinions received in March 2025 for two Opdivo indications: a perioperative regimen for resectable non-small cell lung cancer and a subcutaneous formulation for multiple solid tumors. Also in March 2025, the European Commission approved the expansion of Breyanzi for relapsed or refractory follicular lymphoma. In Addition, late-breaking data from the Phase 3 POETYK PSA-2 trial showed the superiority of Sotyktu over placebo in adults with psoriatic arthritis.